Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

6 Nov 2023

High BMI in late teens linked to higher risk of 17 different cancers later in life

Men who are overweight or obese at age 18 have a higher risk of 17 different cancers later in life. This has been shown in a study at the University of Gothenburg.

6 Nov 2023

Researchers discover new mechanism of cancer treatment resistance

A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators.

2 Nov 2023

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

28 Oct 2023

Groundbreaking research advances understanding of how pathogens impact cancer

Viral infections are known to be a central cause of more than 10% of cancers worldwide. University of California researchers may have uncovered one of the key reasons why.

26 Oct 2023

Red grape polyphenol, resveratrol: a multifaceted therapeutic powerhouse under review

The therapeutic potential of resveratrol, a red grape polyphenol.

25 Oct 2023

"Two-for-one" cancer immunotherapy more effective and at least as safe as standard treatments

A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.

19 Oct 2023

Pregnant and addicted: Homeless women see hope in street medicine

Five days after giving birth, Melissa Crespo was already back on the streets, recovering in a damp, litter-strewn water tunnel, when she got the call from the hospital.

18 Oct 2023

Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine ("Insilico") has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.

16 Oct 2023

Engineered bacteria deliver synthetic targets to solid tumors

For several years, researchers have been successfully using chimeric antigen receptor (CAR) T cells to target specific antigens found on blood cells as a cure for patients with leukemia and lymphoma.

12 Oct 2023

Study finds increased risk of birth defects for offspring of young women with cancer

The offspring of adolescent and young adult women with a history of cancer face a higher risk of birth defects, according to new research from UTHealth Houston.

6 Oct 2023

What are the pharmacological properties of black goji berries?

The pharmacological effects of the components of Lycium ruthenicum Murray fruits.

29 Sep 2023

Weighing the risks and benefits of COVID-19 precautions in 2023

A new editorial paper was published in Oncotarget's Volume 14 on September 22, 2023, entitled, "Reassessing the risks and benefits of COVID-19 precautions in 2023."

28 Sep 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

MGI Partners with National Cancer Centre Singapore to Undergo Comprehensive Genomic Profiling of Asian-Prevalent Cancers

MGI Tech Singapore Pte, Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore ("NCCS") to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI's core DNBSEQ™ technology.

From MGI 18 Sep 2023

Kuano closes £1.8M seed funding round to validate quantum simulation platform for drug discovery

Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, today announced the close of its £1.8M seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other Angel investors.

From Kuano Ltd. 13 Sep 2023

New way to administer CAR-T-cell therapy could lead to fewer side effects

When Richard O'Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy easier on patients.

8 Sep 2023

Did COVID-19 mortality differ between patients with cancer and the general US population depending on which SARS-CoV-2 variant was dominant?

Researchers comparatively evaluated COVID-19 mortality among cancer patients during different periods of the SARS-CoV-2 outbreak.

4 Sep 2023

Universal approach could potentially expand CAR T cell therapy to all blood cancers

A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer.

31 Aug 2023

A comprehensive online resource allows for the exploration of interactions between mutational signatures and topographical features across human cancer

An online resource for studying the relationship between mutational signatures and topographical characteristics across human cancer.

28 Aug 2023